Allspring Global Investments Holdings LLC Has $162.16 Million Stake in argenex SE $ARGX

Allspring Global Investments Holdings LLC lifted its stake in argenex SE (NASDAQ:ARGX) by 14.2% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 211,330 shares of the company’s stock after acquiring an additional 26,343 shares during the period. Allspring Global Investments Holdings LLC’s holdings in argenex were worth $162,160,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Merit Financial Group LLC bought a new position in shares of argenex in the third quarter valued at approximately $266,000. Calamos Advisors LLC boosted its holdings in shares of argenex by 95.8% during the 3rd quarter. Calamos Advisors LLC now owns 5,170 shares of the company’s stock worth $3,813,000 after buying an additional 2,530 shares during the period. Simplify Asset Management Inc. grew its stake in argenex by 13.1% in the 3rd quarter. Simplify Asset Management Inc. now owns 1,659 shares of the company’s stock valued at $1,224,000 after buying an additional 192 shares during the last quarter. Ethic Inc. raised its holdings in argenex by 11.6% in the 3rd quarter. Ethic Inc. now owns 1,119 shares of the company’s stock worth $825,000 after acquiring an additional 116 shares during the period. Finally, SWS Partners lifted its position in argenex by 1.5% during the 3rd quarter. SWS Partners now owns 3,319 shares of the company’s stock worth $2,448,000 after acquiring an additional 49 shares during the last quarter. Institutional investors own 60.32% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on ARGX. Baird R W cut shares of argenex from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 18th. Royal Bank Of Canada boosted their price objective on argenex from $860.00 to $925.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. DZ Bank raised argenex to a “strong-buy” rating in a report on Friday, December 19th. Stifel Nicolaus upped their price target on argenex from $1,028.00 to $1,248.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. Finally, Wall Street Zen raised argenex from a “hold” rating to a “buy” rating in a research report on Friday, October 3rd. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, argenex presently has a consensus rating of “Moderate Buy” and a consensus target price of $982.33.

argenex Trading Up 0.1%

Shares of argenex stock opened at $837.90 on Wednesday. The firm’s 50-day moving average price is $871.38 and its two-hundred day moving average price is $740.94. argenex SE has a 1-year low of $510.05 and a 1-year high of $934.62. The stock has a market capitalization of $51.59 billion, a price-to-earnings ratio of 35.98, a P/E/G ratio of 0.87 and a beta of 0.36.

argenex (NASDAQ:ARGX) last announced its earnings results on Thursday, October 30th. The company reported $4.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.37 by $0.03. The company had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.07 billion. argenex had a net margin of 41.58% and a return on equity of 29.78%. As a group, equities research analysts predict that argenex SE will post 3.13 EPS for the current year.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.